An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
Maria Sole Chimenti,1,* Arianna D’Antonio,1,* Paola Conigliaro,1 Sara Ferrigno,1 Andrea Vendola,1 Mario Ferraioli,1 Paola Triggianese,1 Luisa Costa,2 Francesco Caso,2 Roberto Perricone1 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome T...
Guardado en:
Autores principales: | Chimenti MS, D'Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, Perricone R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9c4966ba5d5b4b01b44f285dac251f29 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
por: Ly K, et al.
Publicado: (2019) -
The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
por: Georgios Kokolakis, et al.
Publicado: (2021) -
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
por: D'Angelo S, et al.
Publicado: (2017) -
Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients
por: Song Zhang, et al.
Publicado: (2021) -
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
por: Harrington R, et al.
Publicado: (2020)